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Available online 4 September 2012Variable lymphocyte receptor (VLR) B antibodies of the evolutionary distant sea lamprey are
structurally distinct from conventional mammalian antibodies. The different protein architecture
and large evolutionary distance of jawless vertebrates suggest that VLR antibodies may represent
promising tools for biomarker discovery. Here we report the generation of panels of monoclonal
VLR antibodies from lamprey larvae immunized with human T cells and the use of a recombinant
monoclonal VLR antibody for antigen purification and mass spectrometric identification. We
demonstrate that despite predicted low affinity of individual VLR antigen binding units to the
antigen, the high avidity resulting from decameric assembly of secreted VLR antibodies allows for
efficient antigen capture and subsequent identification by mass spectometry. We show that VLR
antibodies detect their antigenswith high specificity and can be used in various standard laboratory
application techniques. The lamprey antibodies are novel reagents that can complement conven-
tional monoclonal antibodies in multiple scientific research disciplines.
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The cardinal elements of the adaptive immune system,
including the B cell receptor, T cell receptor and MHC
molecules are found in all jawed vertebrates, but not in jawless
vertebrates (Cooper and Alder, 2006). Although studies
suggesting an adaptive immune system in the evolutionary
distant jawless vertebrates were conducted almost 50 years
ago (Finstad and Good, 1964), the molecular components of
the agnathan adaptive immune system were discovered only
recently (Pancer et al., 2004). Sequence analyses of transcripts
expressed by lymphocyte-like cells of sea lamprey larvae
immunized with a cocktail of plant mitogens and particulate
antigens led to the discovery of the variable lymphocyte
receptor (VLR) B genes, which encode antigen receptors in: +1 416 978 1938.
. Ehrhardt).
Y-NC-ND license. jawless vertebrates. VLRA and VLRC genes were described in
subsequent studies (Rogozin et al., 2007; Guo et al., 2009;
Kasamatsu et al., 2010), accentuating the complexity of the
adaptive immune system of jawless vertebrates.
Unlike mammalian antibodies which use the
immunoglobulin-fold as basic structural unit and are
composed of individual heavy and light chains, VLR anti-
bodies are decameric protein complexes generated by
iteration of a single polypeptide chain containing beta-
sheet forming leucine-rich repeats (LRR) as basic structural
units (Pancer et al., 2004). An incomplete VLR gene in
germline configuration is flanked by a large number of LRR
cassettes, which are copied into thematuring VLR gene by a
gene conversion-like process (Alder et al., 2005; Rogozin et
al., 2007). The mature VLR gene consists of a signal peptide,
a capping N-terminal LRR, followed by a conserved LRR1
unit, 1–9 variable LRRv units, a capping C-terminal LRR unit
and a stalk region, the latter being necessary for cell surface
expression of the VLR antibody and for multimerization of
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Cooper, 2010). Our initial studies on monoclonal VLR
antibodies demonstrated the high degree of specificity
with which VLR antibodies detect their antigen (Herrin et
al., 2008). This specificity is in accordance with a combi-
natorial VLR repertoire predicted to exceed 1014 individual
antibody sequences (Rogozin et al., 2007).
Structural analyses of three monoclonal VLR antibodies
complexed to their respective antigens revealed a solenoid
shape of the individual VLR unit with the antigen interacting
region located at the inner concave surface of the protein (Han
et al., 2008; Velikovsky et al., 2009; Kirchdoerfer et al., 2012).
Importantly, the antigen also makes contact with residues
located in a flexible and highly variable loop structure that
protrudes from the capping C-terminal LRR unit. In the first
solved structure, the VLR antibody forms a pocket for the
comparatively small erythrocyte H-trisaccharide antigen be-
tween the relatively rigid parallel beta-sheets of the VLR
backbone and the flexible C-terminal loop sequences (Han et
al., 2008). In a second study, a hen egg lysozyme (HEL)-specific
VLR antibody was shown to bind the antigen by inserting the
C-terminal VLR loop into the active site of the enzyme in
addition to forming interactions with residues located in the
LRR backbone of the VLR antibody (Velikovsky et al., 2009).
Importantly, these structural analyses indicate that antigen
recognition by VLR antibodies is distinct from antigen recog-
nition by conventional immunoglobulin-based antibodies. The
unique origins and structural characteristics of VLR antibodies
suggest that these proteins have the potential to complement
conventional antibodies in biomedical research applications
and for biomarker discovery studies. Here we describe the
generation of monoclonal VLR antibodies to human T lineage
lymphocytes and demonstrate applicability of monoclonal VLR
antibodies for affinity purification and mass spectrometric
identification of the cell surface antigens.
2. Materials and methods
2.1. Animals and immunizations
Lamprey larvae (80–100 mm, Lamprey Services, Ludington,
MI) in length were anesthetized (0.1 g/l MS222/0.14 g/l
sodium bicarbonate) and immunized with 2×106 primary
lymphocytes enriched for CD4+ T cells in 60 μl of 0.66× PBS.
The animals were boosted twice at 2 week intervals with an
equal number of cells obtained from different donors to avoid
the generation of alloantigen-specific VLRs. 10 days after the
second boost the animals were sacrificed (1 g/l MS222/1.4 g/l
sodium bicarbonate) followed by exsanguination. Peripheral
bloodwas collected in 0.66× PBS/30 mMEDTA, layered on top
of 55% percoll and subjected to density centrifugation (400×g,
20 min). Subsequently, the lamprey lymphocytes were col-
lected and the antisera were analyzed for reactivity to primary
human PBMC. Out of 3 immunized animals, we chose the
animal with the highest polyclonal VLR antibody titer for
subsequent expression library generation.
2.2. Human tissues
Peripheral blood was obtained from healthy volunteers
of the Vaccine Center of Emory University, Atlanta, GA afterinformed consent was obtained. Tonsil samples were ob-
tained from Children's Healthcare of Atlanta and chronic
lymphocytic leukemia (CLL) samples from Emory University
tissue procurement facility. All studies with human tissues
were approved by the Institutional Ethics Review Board and
were conducted in accordance with institutional guidelines
and the declaration of Helsinki.
2.3. Cells and reagents
Tonsilar single cell suspensions were generated by tissue
mincing, filtration through 70 μm wire mesh, and cell centri-
fugation on a ficoll-hypaque gradient. Blood CD4+ T cells were
purified using CD4 microbeads (Miltenyi Biotec, Cambridge,
MA) followed by magnetic separation. Hemopoietic cell
lines weremaintained in RPMI 1640 supplemented with 10%
fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin, and 50 μM β-mercaptoethanol and HEK293T
cells were maintained in DMEM supplemented with 10%
fetal calf serum, 2 mM L-glutamine, and 100 U/ml penicillin/
streptomycin. Antibodies to CD3, CD5 and CD19 were ob-
tained from BD-Biosciences (San Jose, CA). Secondary anti-
bodies were obtained from Southern Biotech (Birmingham,
AL) and the VLR-specific monoclonal antibody 4C4 was
generated in our laboratory (Alder et al., 2005).
2.4. Generation of VLR expression libraries and recombinant VLR
antibodies
RNA was extracted from purified lamprey lymphocytes
using Qiagen RNeasy systems (Qiagen, Valencia, CA). Total RNA
was used as a template for subsequent random-primed cDNA
generation (SuperScript III, Invitrogen, Grand Island, NY),
followed by amplification of VLR sequences with gene specific
oligonucleotides located in the signal peptide (5′-ATATGCT
AGCCACCATGTGGATCAAGTGGATCGCCACGC-3′) and stalk re-
gion (5′-ATATACCGGTTCAACGTTTCCTGCAGAGGGCG-3′) of
the VLR gene. The amplified gene sequences were digested
with the Nhe I and Age I restriction enzymes and cloned into
the expression vector pIRESpuro2 (Invitrogen, Grand Island,
NY). To generate HA/6xHis-tagged VLR antibodies and mono-
meric VLR antibodies we used the alternative antisense primer
sequences 5′- ATATACCGGTTGGGCATTTCGAGGGGCTAGTGCT-3′
and 5′- TATACCGGTTCAGGGTTTCTGGGTTGTGATCAC-3′, respec-
tively. VLR expression constructswere transfected into 293T cells
using polyethylenimine (PEI) at a ratio of 3 μg PEI:1 μg DNA as
described (Reed et al., 2006). 3 days after transfection, the
supernatant was harvested and used for staining of primary
cells and cell lines. Alternatively, 293T cells transfected with
HA/6xHis-tagged VLR clones cells were subjected to
treatment with puromycin (1 μg/ml) and supernatant from
puromycin-resistant cells was used for purification of
recombinant VLR proteins using Ni-NTA columns followed
by elution with 150 mM imidazole.
2.5. Flow cytometric screen of VLR expression library
PBMCs were incubated with VLR containing supernatants
from transfected 293T cells for 30 min on ice. The cells were
washed 2× with PBS/1% BSA followed by incubation with
mouse monoclonal antibody (4C4) with VLR specificity at a
Table 1
Screening results of monoclonal VLR antibodies to PBMCs.
VLR clone T cells B cells Non B/T cells Monocytes
VLR6 + − − −
VLR18 + + + −
VLR25 + + + −
VLR32 + − − −
VLR33 + − +a −
VLR37 + − +a −
VLR73 + − +a −
VLR87 + + + −
VLR97 + − − −
VLR99 − − − +
VLR109 + − +a −
VLR139 + + + −
T cells: CD3+, B cells: CD19+, non B/T cells: CD3−/Cd19−, monocytes
identified by FSC/SSC profile.
a Indicates partial staining of the cell population.
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Subsequently the cells were washed 2× and incubated with
goat anti-mouse PE-labeled secondary antibody. Following
this step, the cells were blocked extensively in 5% normal
mouse serum, stained with anti-human CD3 and CD19
monoclonal antibodies and analyzed on a FACS CyAN
instrument (Dako Cytomation, Carpinteria, CA). FACS data
were analyzed using FloJo software. As negative control we
used the monoclonal VLR4 antibody that specifically reacts
with the BclA antigen of Bacillus anthracis (Herrin et al.,
2008).
2.6. Western blotting and immunoprecipitation
Western blotting and immunoprecipitation experiments
with Jurkat cells and transfected 293T cells were performed
as described previously with minor modifications (Ehrhardt
et al., 2005). Briefly, cells were pelleted and resuspended in
lysis buffer containing 1% Nonidet P-40, 50 mM Tris·HCl
(pH 7.5), 5 mM EDTA, 150 mM NaCl, and the protease
inhibitors leupeptin (5 μg/ml), pepstatin (1 μg/ml), aprotinin
(5 μg/ml), PMSF (40 μg/ml). The whole cell lysates were
incubated with 20 μl of a 50% slurry of protein G beads (GE
Biosciences) which were pre-coated with anti-HA antibody
12CA5 and the indicated monoclonal VLR antibodies. After
over-night incubation at 4 °C the beads were washed 3–5
times with lysis buffer and either further processed for mass
spectrometric analysis or boiled in SDS-sample loading
buffer. Immunoadsorbed proteins were resolved by SDS/
PAGE before the transfer to nitrocellulose membranes (PALL
BioSciences, Ville St. Laurent, Quebec, Canada), which were
probed with the indicated antibodies and visualized by using
the ECL reagent (Millipore, Billerica, MA).
2.7. LC–MS/MS sample preparation and analysis
VLR32 immunoprecipitates and control precipitates
consisting of Jurkat cell lysates incubated with anti-HA
antibodies and protein G beads were eluted in 8 M urea/
100 mM ammonium bicarbonate at 95 °C. Eluates were
reduced with 10 mM DTT for 20 min at 60 °C, allowed to
cool at room temperature, and alkylated with 10 mM
iodoacetamide for 15 min at room temperature in the dark.
Samples were diluted 4-fold in 100 mM ammonium bicar-
bonate to reach a concentration of ≤2 mM urea prior to
overnight proteolytic digest with 10 mg/ml trypsin at room
temperature. The resulting tryptic peptide samples were
acidified with trifluoroacetic acid at a final concentration of
1% prior to desalting and purification using offline C18
reverse-phase chromatography. Samples were then dried in
a vacuum centrifuge and re-dissolved in 0.1% formic acid for
LC–MS/MS analysis. Inline C18 reverse-phase chromatogra-
phy was performed over a 120-minute gradient using an
integrated nano-LC system (Easy-nLC, Proxeon Biosystems
A/S, Odense, Denmark), coupled to a linear ion trap-Orbitrap
hybrid mass spectrometer instrument (LTQ-Orbitrap, Thermo,
San Jose, CA). Profile mode MS spectra were acquired at a
60,000 full-width half-maximum (FWHM) resolution in the
Orbitrap whereas MS/MS spectra were acquired in the
linear ion trap.2.8. Data base search and protein identiﬁcation
Tandem mass spectra were extracted from the raw data
files (.RAW) using Mascot (Matrix Science, London, UK;
version Mascot) and X! Tandem (The GPM, thegpm.org;
version CYCLONE (2010.12.01.1)) engines to search the
ipi.HUMAN.v3.87 database (91464 entries) assuming trypsin
digest and allowing a maximum of 1 miss cleavage. Search
was performed with a fragment (MS/MS) ion mass tolerance
of 0.50 Da and a parent (MS) ion tolerance of 10.0 ppm.
Carbamidomethylation of cysteine was specified as a fixed
modification and oxidation of methionine was specified as a
variable modification. Scaffold (version Scaffold_3.3.1, Prote-
ome Software Inc., Portland, OR) was used to validate MS/
MS-based peptide and protein identifications. Peptide iden-
tifications were accepted if they exceeded specific database
search engine thresholds. Mascot identifications required at
least ion scores must be greater than both the associated
identity scores and 20. X! Tandem identifications required at
least−Log(Expect Scores) scores of greater than 2.0. Protein
identifications were accepted if they contained at least 2
identified peptides. Proteins that contained similar peptides
and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony.
3. Results
In an effort to generate monoclonal VLR antibodies against
human T lineage cells we immunized lamprey larvae with
CD4+ T cells purified from peripheral blood samples. We
screened 151 monoclonal VLR antibodies for binding to
peripheral blood mononuclear cells (PBMC). Twelve clones
recognized various populations of PBMCs in flow cytometry
analyses (Table 1). Three of these (VLR6, VLR32 and VLR97)
displayed a T cell-specific binding pattern, whereas the
remaining 9 monoclonal VLR antibodies also bound to other
PBMC populations. Because of the comparatively weak T
cell-specific signal obtained with VLR6 and VLR97 (data not
shown) we selected VLR32 for further analysis (Fig. 1A). This
monoclonal VLR antibody contains 3 LRRV segments and is
thus slightly larger than the average VLR protein (Fig. 1B). To
facilitate purification and manipulation of this reagent in
further studies, we engineered the 6xHis tag and the HA
Fig. 1. Representative staining patterns of monoclonal VLR antibodies and VLR32 protein sequence. (A) Immunofluorescence staining of PBMC with monoclonal
VLR32, VLR37 and VLR87. VLR binding to B cells (CD19+), T cells (CD3+) and non-B/T cells (CD19−/CD3−) is depicted by a black histogram. Staining with
negative control VLR4 (specific for B. anthracis BclA) is indicated by a filled gray histogram. (B) Schematic and protein sequence of human T cell binding VLR32.
Note the inclusion of the HA and 6xHis epitope tags that was engineered into the invariant stalk region to facilitate purification and detection of recombinant VLR
antibodies.
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Inclusion of these sequences did not alter its binding specificity
(data not shown).
We further defined the binding specificity of the monoclo-
nal VLR32 antibody by immunophenotyping panels of cell linesFig. 2. Reactivity of VLR32 with cells expressing human CD5. (A) Immunofluoresce
depicted by a black histogram. Staining with the control lamprey VLR4 antibody is in
row) and CD3+ T cells (bottom row) with negative control VLR4 (left), VLR32 (c
representative of 4 analyzed tonsil samples. (C) Co-staining of VLR32 or VLR4 with m
analyzed tonsilar tissue samples and 2 analyzed B-CLL samples.and primary cells with this reagent. Among the different cell
lines tested, only T lineage cell lines stained positive for VLR32
binding (Fig. 2A). Similarly, T lineage cells from peripheral
blood reacted with this antibody (Fig. 1A). When the reactivity
of this VLR antibody was examined against tissue-basednce staining of human hemopoietic cell lines with VLR32. VLR32 binding is
dicated by a filled gray histogram. (B) Staining of tonsilar CD19+ B cells (top
enter) or monoclonal mouse anti-human CD5 antibody (right). Shown is a
onoclonal mouse anti-human CD5 antibody. Shown are representatives of 4
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of the tonsilar CD3+ cells (Fig. 2B). In addition, a small
population of tonsilar B lineage cells also bound VLR32
(Fig. 2B top row, center), a potentially informative observation
in that a subpopulation of tonsilar B cells co-expresses the CD5
antigen (Fig. 2B, top row, right) (Dono et al., 1996, 2007).
Indeed, B cell reactivity of the VLR32 antibody was found to be
restricted to CD5 expressing cells (Fig. 2C). Furthermore, when
we tested reactivity of monoclonal VLR32 with primary
malignant CLL cells, which characteristically express the CD5
antigen, all CD5+ CLL cells from two patients were detected
(Fig. 2C, right panel). These results demonstrated selective
reactivity of monoclonal VLR32 antibody with cells expressing
the CD5 antigen.
Our analysis thus indicated that the antigen detected by this
VLR antibody is either CD5 or an antigen that is co-expressed
with the CD5 antigen. To determine the identity of the antigen
recognized by VLR32, we used this VLR antibody to immuno-
precipitate the antigen from Jurkat T cells followed by tandem
mass spectrometry. The precipitates were digested with tryp-
sin and the resulting tryptic peptides were analyzed by liquid
chromatography-tandem mass spectrometry (LC–MS/MS) for
identification. A total of 10 peptide fragmentation spectra from
9 different peptides were assigned to CD5. These peptides
corresponded to protein sequence coverage of 26%, allowing its
identificationwith a confidence value of over 99%. Importantly,
CD5 was one of only two proteins identified with at least 2
peptides specifically in the VLR32-containing IP compared to
the ‘minus-VLR32’ negative control. The other identified
protein, myosin-9 was only identified with 2 spectra from 2
unique peptides, corresponding to a sequence coverage of only
1%. Using this approach we determined that VLR32 immuno-
precipitations contained the CD5 antigen (Table 2).We verified
these results in parallel experiments testing the reactivity of
VLR32 with cells transfected with CD5–GFP fusion constructs,
by western blot analysis and immunoprecipitation experi-
ments. VLR32, but not the negative control VLR4, was able to
detect CD5–GFP fusion proteins in cell lysates from transiently
transfected HEK293T cells (Fig. 3A). This reactivity was limited
to lysates separated under non-reducing conditions as separa-
tion of cell lysates under reducing conditions abolished VLR32
binding (data not shown). In additional experiments, we
demonstrated that VLR32 but not the negative control VLR4
precipitated CD5–GFP fusion proteins from cell lysates of
transiently transfected HEK293T cells (Fig. 3B) and that
VLR32 but not VLR4 stained HEK293T cells transfected with
CD5 expression constructs in flow cytometry experiments
(Fig. 3C). These experiments demonstrate the CD5-specificity
of VLR32.Table 2
Mass spectrometric analysis of VLR32 immunoprecipitates.
Rank Access. no. Protein Unique
peptides
Total
peptides
(+) (−) (+) (−)
1 IPI000253 CD5 T-cell glycoprotein 9 0 10 0
2 IPI000195 Isoform 1 of Myosin-9 2 0 2 0
Numbers of identified peptides. (+), immunoprecipitates performed in the
presence of VLR32; (−), immunoprecipitates performed in the absence of VLR32.Prior studies of VLR antibodies suggest that binding of the
antibody to the antigen is avidity-based and that the affinity of
the individual antigen-binding unit to the antigen is often
comparatively low (Herrin et al., 2008; Kirchdoerfer et al.,
2012). To investigate the affinity versus avidity-based binding
of VLR32 to the CD5 antigen, we generated monomeric VLR32
antibodies by deleting the C-terminal 42 residues of the VLR
antibody. As expected, the resulting individual VLR units
displayed a slightly faster migration pattern compared to
full-length VLR proteins (Fig. 3B). Only the multimeric VLR32
was able to bind to CD5 efficiently as shown for immunopre-
cipitation (Fig. 3B) and flow cytometry analyses (Fig. 3D). VLR
binding was not detected by flow cytometry using the
monomeric VLR32 (Fig. 3D) and only a weak signal was
obtained for immunoprecipitated CD5–GFP using the mono-
meric VLR32 (Fig. 3B). These data indicate an avidity-based
contribution to the binding of the VLR32 lamprey antibody to
human CD5.
4. Discussion
In this study, we demonstrate for the first time that
monoclonal lamprey VLR antibodies can be used for
purification and mass spectrometry-based identification of
cell surface expressed protein antigens. Unlike conventional
immunoglobulin-based antibodies, VLR antibodies utilize their
leucine-rich repeats as basic structural units, resulting in a
fundamentally different protein architecture of antigen re-
ceptors. Structural analyses of monoclonal VLR antibodies
specific for the erythrocyte H-trisaccharide, HEL and Bcl-A
coat protein display antibody–antigen interactions that are
distinct from antigen–antibody interactions observed for
conventional mammalian antibodies. A flexible loop-structure
protruding from the C-terminal LRR capping unit of the VLR
antibody forms a pocket for the relatively small H-trisaccharide
antigen which interacts with residues located in the inner
concave surface of the VLR antibody and the C-terminal loop.
On the other hand, the C-terminal loop interacts with residues
located in the active site of HEL, an epitope location to which it
is notoriously difficult to raise conventional immunoglobulin-
based antibodies, which preferentially interact with planar
epitopes. We hypothesize that the unique origins and protein
architecture of VLR antibodies will render these novel reagents
uniquely suited for biomarker discovery. Key to using mono-
clonal VLR antibodies for this purposewill be their applicability
for the capture and purification of protein antigens. Using the
monoclonal VLR32 antibody, we demonstrate that lamprey
antibodies can be used effectively for immunoprecipitation
applications followed by mass spectrometric protein identifi-
cation. The inability of a monomeric form of the VLR antibody
to bind to Jurkat T cells indicates its low affinity, in keeping
with recent analyses indicating a Kd of 3.0×10−6 M for
monomeric units of the VLR4 antibody (Kirchdoerfer et al.,
2012). However, our data show that a low affinity of the
individual antigen-binding unit to the antigen does not impede
the use of multimeric VLR antibodies for protein purification.
We observed a weak signal for CD5–GFP fusion proteins in
immunoprecipitation experiments using monomeric VLR anti-
bodies, which is likely due to ‘artificial’ multimerization of
these VLR units upon binding to protein G beads. This type of
‘artificial’ multimerization would not occur in flow cytometry
Fig. 3. VLR32 specifically recognizes human CD5. (A)Western blot of lysates of 293T cells transfectedwith human CD5–GFP fusion constructs or untransfected control
cells. Cell lysates were separated under non-reducing conditions and immunoblotted (IB) with the indicated antibodies. The position of the CD5–GFP fusion protein is
indicated by an arrowhead. The bottom section of the membrane was probed with anti-actin antibodies to verify equal loading. (B) Immunoprecipitation of CD5–GFP
fusion proteins with VLR32. Lysates of 293T cells transfected with human CD5–GFP fusion constructs or lysates of untransfected control cells were subjected to
immunoprecipitation with multimeric VLR4, monomeric VLR32 or multimeric VLR32. The cell lysates (bottom panels) and immunoprecipitates (top panels) were
separated by SDS–PAGE under reducing conditions and were probed with anti-GFP antibodies to detect CD5-fusion proteins, anti-HA tag antibodies to detect VLR
proteins and anti-actin antibodies to verify loading of the whole cell lysates. An arrowhead indicates immunoprecipitated CD5–GFP fusion proteins. Shown is a
representative of 4 independent experiments. (C) Detection of cell surface CD5 on transiently transfected HEK293T cells by VLR32. HEK293T cells were stained with
VLR32, negative control VLR4, and mouse monoclonal anti-CD5 antibody to analyze binding specificity of VLR32. (D) Detection of cell surface CD5 on Jurkat T
cells with multimeric but not monomeric VLR32. VLR32 binding is depicted by a black histogram. Staining of cells with multimeric negative control VLR4 is
indicated by a filled gray histogram.
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recombinant monomeric VLR32 units.
CD5 positive human B cells have been described previously
in tonsilar tissues (Fischer et al., 1997) and other reports
indicate a comparable proportion of peripheral blood B cells
(10–25%) expressing the CD5 antigen (Gadol and Ault, 1986;
Ebeling et al., 1993). While tonsilar CD5-positive B cells were
readily detected using monoclonal VLR32, we did not detect B
cells that boundVLR32 in our initial screen of the VLR library on
PBMCs. However, in subsequent experiments we observed a
significant inter-person variability of CD5+ cells in blood and
found that VLR32 can recognize CD5+ B cells in blood (data not
shown), suggesting that the lack of VLR32-bindingB cells in our
original screen is likely reflective of a donor sample devoid of a
substantial CD5+ B cell population.
In conclusion, we present monoclonal VLR antibodies as
novel reagents for proteomics-based biomarker identification.
The unique origins and protein architecture of these reagents
raise the possibility that VLR antibodies may recognize anti-
gens against which conventional antibodies cannot readily be
generated due to structural or tolerogenic reasons. VLR anti-
bodies may thus serve as valuable reagents for biomarkerdiscovery and as complements in existing panels of conven-
tional antibodies.
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